August 8, 2007 – A new report from IMV Limited suggests controversy among urologists and radiation oncologists regarding optimal treatments for patients with localized prostate cancer.
The report, Trends in the Prostate Cancer Treatment Market: 2007 and Beyond, is based on new primary market research involving 122 urologists and 115 radiation oncologists in the U.S. who actively treat prostate cancer patients. The report provides insights about procedure volumes, opinions about the relative efficacy of different therapies and rating of brachytherapy seed vendors on attributes such as product quality and customer service.
“In general, less invasive treatment modalities will continue to gain favor. Both urologists and radiation oncologists expect the use of Image Guided Radiation Therapy (IGRT) to become much more widespread within the next few years, leading to more focused treatment that will be delivered in fewer sessions,” observed Mary. C. Patton, Director of Market Research at IMV. “But unlike the radiation oncologist, many urologists predict that the use of laparoscopic radical prostatectomy will grow significantly in the near future, taking advantage of nerve-sparing techniques and robotic assistance to reinforce surgery as their first-line treatment of choice for patients with localized disease.”
For more information: www.imvinfo.com